X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3066) 3066
female (2951) 2951
estrogen plus progestin (2746) 2746
postmenopausal women (2081) 2081
index medicus (1760) 1760
middle aged (1559) 1559
hormone replacement therapy (1268) 1268
menopause (1164) 1164
randomized controlled-trial (1157) 1157
obstetrics & gynecology (1156) 1156
aged (1074) 1074
risk factors (963) 963
plus progestin (886) 886
coronary-heart-disease (796) 796
risk (751) 751
hormone therapy (750) 750
replacement therapy (743) 743
estrogen (684) 684
postmenopause (654) 654
women (652) 652
estrogen replacement therapy - adverse effects (598) 598
estrogen replacement therapy (574) 574
animals (573) 573
oncology (553) 553
adult (552) 552
breast cancer (527) 527
cardiovascular-disease (503) 503
endocrinology & metabolism (501) 501
health aspects (498) 498
healthy postmenopausal women (490) 490
prevention (457) 457
medicine, general & internal (439) 439
male (406) 406
breast-cancer (405) 405
women's health (405) 405
cancer (364) 364
randomized controlled trials as topic (341) 341
article (333) 333
conjugated equine estrogens (333) 333
research (323) 323
trial (322) 322
womens health (305) 305
osteoporosis (292) 292
geriatrics & gerontology (281) 281
bone-mineral density (277) 277
pharmacology & pharmacy (274) 274
breast neoplasms - epidemiology (270) 270
care and treatment (266) 266
estradiol (266) 266
health (264) 264
health initiative memory (264) 264
treatment outcome (264) 264
risk assessment (261) 261
hormones (258) 258
public, environmental & occupational health (257) 257
randomized-trial (257) 257
double-blind (241) 241
hormone-replacement therapy (241) 241
quality-of-life (240) 240
medroxyprogesterone acetate (235) 235
cardiac & cardiovascular systems (233) 233
internal medicine (232) 232
incidence (228) 228
mortality (227) 227
rats (227) 227
estrogen replacement therapy - methods (225) 225
time factors (224) 224
progesterone (220) 220
age factors (218) 218
disease (215) 215
double-blind method (215) 215
atherosclerosis (214) 214
hormone replacement therapy - adverse effects (214) 214
prospective studies (210) 210
cardiovascular disease (209) 209
estrogens - administration & dosage (207) 207
peripheral vascular disease (207) 207
cardiovascular diseases - prevention & control (203) 203
estrogens - therapeutic use (202) 202
heart-disease (202) 202
aged, 80 and over (201) 201
estrogens (198) 198
estradiol - administration & dosage (195) 195
abridged index medicus (192) 192
analysis (192) 192
epidemiology (190) 190
ovariectomy (189) 189
mammography (186) 186
breast neoplasms - chemically induced (185) 185
cohort studies (185) 185
estradiol - pharmacology (182) 182
quality of life (181) 181
case-control studies (179) 179
risk-factors (177) 177
surveys and questionnaires (173) 173
therapy (169) 169
postmenopause - drug effects (168) 168
medicine & public health (167) 167
united-states (166) 166
estrogens - adverse effects (165) 165
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3905) 3905
French (43) 43
German (30) 30
Spanish (19) 19
Polish (18) 18
Russian (9) 9
Portuguese (6) 6
Slovenian (6) 6
Japanese (2) 2
Czech (1) 1
Italian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 07/2002, Volume 288, Issue 1, pp. 58 - 64
Journal Article
Journal Article
Menopause, ISSN 1072-3714, 03/2010, Volume 17, Issue 2, pp. 242 - 255
Journal Article
Nature, ISSN 0028-0836, 11/2010, Volume 468, Issue 7320, pp. 98 - 102
Breast cancer is one of the most common cancers in humans and will on average affect up to one in eight women in their lifetime in the United States and... 
EPITHELIAL-CELLS | OSTEOPROTEGERIN-LIGAND | MULTIDISCIPLINARY SCIENCES | MEDROXYPROGESTERONE ACETATE | RECEPTOR ACTIVATOR | HORMONE-REPLACEMENT THERAPY | STEM-CELL | BONE METASTASIS | POSTMENOPAUSAL WOMEN | GLAND DEVELOPMENT | ESTROGEN-PLUS-PROGESTIN | Phosphoproteins - immunology | Gamma Rays | Epithelial Cells - metabolism | RANK Ligand - metabolism | Apoptosis - radiation effects | Epithelial Cells - drug effects | Progestins - adverse effects | NF-kappa B - metabolism | Stem Cells - cytology | Mammary Neoplasms, Experimental - metabolism | Osteoclasts - cytology | Stem Cells - metabolism | Mammary Neoplasms, Experimental - genetics | Receptor Activator of Nuclear Factor-kappa B - deficiency | Phosphoproteins - analysis | Mammary Neoplasms, Experimental - pathology | Medroxyprogesterone Acetate - adverse effects | Female | Cell Differentiation | Receptor Activator of Nuclear Factor-kappa B - metabolism | Epithelial Cells - cytology | Epithelial Cells - radiation effects | Signal Transduction | Mammary Neoplasms, Experimental - chemically induced | RANK Ligand - genetics | Integrin alpha6 - metabolism | Animals | Progestins - administration & dosage | Receptor Activator of Nuclear Factor-kappa B - genetics | Stem Cells - drug effects | RANK Ligand - deficiency | Cell Proliferation - drug effects | Medroxyprogesterone Acetate - administration & dosage | Mice | DNA Damage | Prevention | Complications and side effects | Care and treatment | Hormone therapy | Medroxyprogesterone | Development and progression | Breast cancer | Research | Cell differentiation | Health aspects | Risk factors | Cancer | Proteins | Womens health | Rodents | Cell cycle | Mammography | Females | Apoptosis
Journal Article
Menopause, ISSN 1072-3714, 07/2008, Volume 15, Issue 4, pp. 584 - 602
Objective: To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in... 
Hormone therapy | Vaginal atrophy | Menopause | Venous thromboembolism-Stroke | Estrogen | Total mortality | Coronary heart disease | Sexual function-Urinary health | Quality of life | Vasomotor symptoms | Osteoporosis | Progestogen | Perimenopause | Hormone replacement therapy | estrogen | CONJUGATED EQUINE ESTROGENS | mood | BONE-MINERAL DENSITY | diabetes mellitus | RANDOMIZED CONTROLLED-TRIAL | cognitive decline | premature ovarian failure | OBSTETRICS & GYNECOLOGY | sexual function | menopause | PLUS-PROGESTIN | total mortality | perimenopause | urinary health | HORMONE-REPLACEMENT THERAPY | HEALTHY OLDER WOMEN | vaginal atrophy | hormone therapy | premature menopause | postmenopause | QUALITY-OF-LIFE | progestogen | bioidentical hormones | breast cancer | osteoporosis | stroke | DOSE TRANSDERMAL ESTRADIOL | Women's Health Initiative | vasomotor symptoms | BREAST-CANCER RISK | venous thromboembolism | hormone replacement therapy | endometrial cancer | dementia | coronary heart disease | depression | quality of life | CORONARY-HEART-DISEASE | NAMS | Postmenopause | Female | Humans | Estrogen Replacement Therapy - adverse effects | Contraindications | Index Medicus | Endometrial cancer | Cognitive decline | Sexual function | Venous thromboembolism | Urinary health | Stroke | Bioidentical hormones | Diabetes mellitus | Premature ovarian failure | Depression | Breast cancer | Premature menopause | Women’s Health Initiative | Mood | Dementia
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 02/2007, Volume 115, Issue 7, pp. 840 - 845
Journal Article
Journal Article